Publications
1.
Liu, Richard; Abraham, Rahul; Conderino, Sarah; Kanchi, Rania; Blecker, Saul; Dodson, John A.; Thorpe, Lorna E.; Charytan, David M.; DeMarco, Mara A. McAdams; Wu, Wenbo
COVID‑19 Pandemic‑Induced Healthcare Disruption and Chronic Kidney Disease Progression Journal Article
In: Journal of General Internal Medicine, 2025.
Abstract | Links | BibTeX | Tags: chronic kidney disease progression, COVID-19
@article{nokey,
title = {COVID‑19 Pandemic‑Induced Healthcare Disruption and Chronic Kidney Disease Progression},
author = {Richard Liu and Rahul Abraham and Sarah Conderino and Rania Kanchi and Saul Blecker and John A. Dodson and Lorna E. Thorpe and David M. Charytan and Mara A. McAdams DeMarco and Wenbo Wu},
doi = {https://doi.org/10.1007/s11606-025-09832-9},
year = {2025},
date = {2025-09-04},
urldate = {2025-09-04},
journal = {Journal of General Internal Medicine},
abstract = {Introduction
The coronavirus disease 2019 (COVID-19) pandemic caused unprecedented disruptions to healthcare systems worldwide, significantly affecting patients with chronic kidney disease (CKD). In this study, we evaluated the impact of the pandemic on healthcare-seeking behavior and CKD progression among patients in New York City.
Methods
Using electronic health records from PCORnet’s INSIGHT Clinical Research Network, we conducted a retrospective cohort study focused on 84,062 patients with CKD aged 50 years or older with multiple chronic conditions seen between 2017 and 2022. Patients were identified using pre-pandemic CKD diagnostic codes, and confirmed by estimated glomerular filtration rate (eGFR) measurements. Care disruption was defined as receiving fewer visits than recommended by Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. We used linear mixed-effects models to estimate annual eGFR changes and analyze trends in care visits stratified by CKD stage and care disruption.
Results
The study cohort had a mean age of 75.8 years, 43.2% were male, and mean pre-pandemic eGFR was 51.1 mL/min/1.73 m2. Care visits declined sharply in 2020 across patients at all but the end stage, with incomplete recovery by 2022. Patients with adequate pre-pandemic care maintained their visits above KDIGO levels, while those with inadequate care increased visits during the pandemic. Pronounced eGFR decline occurred in 2020 (10.6%), with slower declines observed thereafter.
Conclusion
The COVID-19 pandemic disrupted CKD care, potentially leading to reduced healthcare-seeking behavior and accelerated kidney function decline in 2020. Slower decline post-2020 may reflect improved healthcare utilization, better medication adherence, and new therapies, and other factors.},
keywords = {chronic kidney disease progression, COVID-19},
pubstate = {published},
tppubtype = {article}
}
Introduction
The coronavirus disease 2019 (COVID-19) pandemic caused unprecedented disruptions to healthcare systems worldwide, significantly affecting patients with chronic kidney disease (CKD). In this study, we evaluated the impact of the pandemic on healthcare-seeking behavior and CKD progression among patients in New York City.
Methods
Using electronic health records from PCORnet’s INSIGHT Clinical Research Network, we conducted a retrospective cohort study focused on 84,062 patients with CKD aged 50 years or older with multiple chronic conditions seen between 2017 and 2022. Patients were identified using pre-pandemic CKD diagnostic codes, and confirmed by estimated glomerular filtration rate (eGFR) measurements. Care disruption was defined as receiving fewer visits than recommended by Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. We used linear mixed-effects models to estimate annual eGFR changes and analyze trends in care visits stratified by CKD stage and care disruption.
Results
The study cohort had a mean age of 75.8 years, 43.2% were male, and mean pre-pandemic eGFR was 51.1 mL/min/1.73 m2. Care visits declined sharply in 2020 across patients at all but the end stage, with incomplete recovery by 2022. Patients with adequate pre-pandemic care maintained their visits above KDIGO levels, while those with inadequate care increased visits during the pandemic. Pronounced eGFR decline occurred in 2020 (10.6%), with slower declines observed thereafter.
Conclusion
The COVID-19 pandemic disrupted CKD care, potentially leading to reduced healthcare-seeking behavior and accelerated kidney function decline in 2020. Slower decline post-2020 may reflect improved healthcare utilization, better medication adherence, and new therapies, and other factors.
The coronavirus disease 2019 (COVID-19) pandemic caused unprecedented disruptions to healthcare systems worldwide, significantly affecting patients with chronic kidney disease (CKD). In this study, we evaluated the impact of the pandemic on healthcare-seeking behavior and CKD progression among patients in New York City.
Methods
Using electronic health records from PCORnet’s INSIGHT Clinical Research Network, we conducted a retrospective cohort study focused on 84,062 patients with CKD aged 50 years or older with multiple chronic conditions seen between 2017 and 2022. Patients were identified using pre-pandemic CKD diagnostic codes, and confirmed by estimated glomerular filtration rate (eGFR) measurements. Care disruption was defined as receiving fewer visits than recommended by Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. We used linear mixed-effects models to estimate annual eGFR changes and analyze trends in care visits stratified by CKD stage and care disruption.
Results
The study cohort had a mean age of 75.8 years, 43.2% were male, and mean pre-pandemic eGFR was 51.1 mL/min/1.73 m2. Care visits declined sharply in 2020 across patients at all but the end stage, with incomplete recovery by 2022. Patients with adequate pre-pandemic care maintained their visits above KDIGO levels, while those with inadequate care increased visits during the pandemic. Pronounced eGFR decline occurred in 2020 (10.6%), with slower declines observed thereafter.
Conclusion
The COVID-19 pandemic disrupted CKD care, potentially leading to reduced healthcare-seeking behavior and accelerated kidney function decline in 2020. Slower decline post-2020 may reflect improved healthcare utilization, better medication adherence, and new therapies, and other factors.